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Cytochrome P450 (CYP) phenotyping describes ac-tual drug-metabolizing enzyme activity at any
point in time.1 Phenotyping studies are used to esti-
mate enzyme activity by correlating biomarker clear-
ance to the amount of enzyme present.2 Intravenous
(IV) midazolam is used as a hepatic cytochrome P450
3A (CYP3A) phenotyping biomarker.2,3 Conven-
tionally, CYP3A activity is characterized by collecting
multiplemidazolamplasma concentrations over a 6- to
8-hour period to determine midazolam total systemic
clearance (CL).2,4 Multiple plasma samples are costly
and inconvenient, and therefore the use of minimized
sampling has been investigated. Minimized sampling
of plasmamidazolamhas been shown to be highly pre-
dictive (r 2 = 0.95) of midazolam AUC using three sam-
ples.5 However, the use of a single plasma sample
would be optimal. It wouldminimize assay costs and
subject and staff time involvement. Data in liver
transplant patients suggest that the plasma
1’-hydroxymidazolam:midazolam concentration ratio
30minutes following administration of an intravenous
bolus dose of midazolam is predictive (r 2 = 0.76) of
midazolam CL.6
The purpose of this study was to determine if a
single 1’-hydroxymidazolam sample or 1’-hydroxy-
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The 30-minute ratio of 1’-hydroxymidazolam:midazolam
plasma concentrations has been used as a measure of
midazolam clearance in liver transplant patients. This study
determined if a single concentration of 1’-hydroxymidazolam
or the ratio of 1’-hydroxymidazolam:midazolam could be
used to predict midazolam clearance in healthy subjects.
Plasma midazolam and 1’-hydroxymidazolam concentra-
tions from threeprevious studieswereused for analyses.Data
obtainedpredose andat 5, 30, 60, 120, 240, 300, and360min-
utes following intravenous doses of midazolam in 61 adults
were divided and used to derive and validate equations to
predict midazolam clearance. Equations were derived using
linear regression and then validated by comparing predicted
to observed clearance. Only one equation was related to
midazolamclearance as a functionof 1’-hydroxymidazolam,
but it did not predict midazolam clearance (r = 0.29, p =
0.31). Single sampling of 1’-hydroxymidazolam or
1’-hydroxymidazolam:midazolam plasma concentrations
cannot be used to predict midazolam clearance in healthy
adults.
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midazolam:midazolam plasma sample ratio predicts
midazolam CL in healthy adults.
MATERIALS AND METHODS
Data from three previous studies, collected at two insti-
tutions (Bassett Healthcare andVanderbilt University),
were compiled and used for these analyses. Details of
the original studieshavepreviously beenpublished.1,4,7
A total of 61 healthy adults received an IV bolus of
midazolam. The doses ranged from 1.0 to 3.1 mg. Sub-
jects at Bassett Healthcare received midazolam 0.025
mg/kg, while subjects at Vanderbilt University re-
ceived a 1 mg dose regardless of body weight.
Subjects
Bassett Healthcare. Data from 33 healthy adults
were used for these analyses. In brief, subjects under-
went a medical history and physical exam prior to
study participation. Subjects were nonsmokers and
consumed nomore than one 12-ounce beverage of beer
or alcoholic equivalent per day. Subjects received IV
midazolam 0.025 mg/kg (Versed®: 2 mg/ml for injec-
tion, Hoffman-LaRoche, Nutley, NJ) infused over 60
seconds via an antecubital vein. Then, 7ml blood sam-
ples were collected into EDTA-containing tubes
predose andat 5, 30, 60, 120, 240, 300, and360minutes
followingmidazolam administration via an IV catheter
placed in the contralateral arm. Blood samples were
centrifuged. The plasma was frozen at –80°C until
analysis.
Vanderbilt University. Data from 28 healthy volun-
teers were used for the analyses. Subjects were non-
smokers andweremedication free for the duration of
the study. Subjects had medical histories, physical
examinations, and blood work analyses prior to
study participation. Subjects were given 1 mg of IV
[15N3]-labeled midazolam infused over 15 to 30 sec-
onds. Blood samples were obtained predose and at 5,
10, 15, 30, 60, 90, 120, 180, 240, 300, 360, and 480min-
utes following IVmidazolamadministration. Collected
samples were centrifuged. Plasma was frozen at –20°C
until analysis.
Analytical Procedure
Plasma samples were analyzed for midazolam and
1’-hydroxymidazolam concentrations using liquid
chromatography/tandem mass spectrometry
(LC/MS/MS). Analyses of the plasma samples col-
lected at Bassett Healthcare were performed at Oneida
Research Services, Inc. (Whitesboro, NY). Details of
these procedures have previously been published.4,8
Interassay accuracy of the LC/MS/MS assay ranged
from5.73%to9.20%ofnominal values. Interassaypre-
cision of the method was ≤ 9.89% at quality control
sample concentrations of 0.75, 7.5, and 75.0 ng/ml.
Analyses of these plasma samples did not include a
β-glucuronidase incubation period. As a result, only
unconjugated plasma 1’-hydroxymidazolam was
quantified.
Samples collected at Vanderbilt University were
assayed on site. The LC/MS/MS assay interday
reproducibility was < 12%. Analyses of the plasma
samples included a β-glucuronidase incubation
per iod, allowing for quantification of total
1’-hydroxymidazolam.7
Since the 1’-hydroxymidazolam concentrations
were not comparable, the data from each institution
were analyzed separately. Subsequent data groups are
designated as unconjugated 1’-hydroxymidazolamand
total 1’-hydroxymidazolam.
Pharmacokinetic Analysis
Midazolam AUC0-∞ were determined using the trape-
zoidal rulewith extrapolation to infinity of the lastmea-
sured midazolam concentration. The unconjugated
1’-hydroxymidazolam data were analyzed using
TOPFIT 2.0 (Gustav Fischer Verlag, Stuttgart, Ger-
many). The total 1’-hydroxymidazolam data were ana-
lyzed using NCOMP.7 Midazolam clearance was deter-
mined as (midazolam dose)/AUC0-∞.
Data Analysis
Models to predict midazolam CL as a function of a sin-
gle postdose concentration of 1’-hydroxymidazolam or
the ratio of 1’-hydroxymidazolam:midazolam concen-
trations were derived using stepwise multiple linear
regression (SAS 6.12, SAS Institute, Cary, NC). Six-
teen of the 33 subjects from the unconjugated
1’-hydroxymidazolam group and 14 of the 28 subjects
from the total 1’-hydroxymidazolam group were ran-
domly selected and their data used to generate model
equations.p-values ≤0.05were considered statistically
significant. Regression coefficients (r2) for the derived
equations were determined. The derived equations
were then validated with data from the remaining sub-
jects by comparing predicted CL to observed CL using
the Pearson correlation coefficient (r). The Wilcoxon
signed rank test (SigmaStat 2.03, SPSS, Inc., Chicago)
was used to determine statistically significant differ-
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ences between demographic data for each group (deri-
vation and validation).
RESULTS
Demographic data for the derivation and validation
groups are shown in Table I.
Single sampling strategies were investigated at all
time points (i.e., 5, 30, 60, 120, 240, 300, and 360
min) following the dose of midazolam. No model de-
rived from the unconjugated 1’-hydroxymidazolam
data, using 1’-hydroxymidazolam or 1’-hydroxy-
midazolam:midazolam, was predictive of midazolam
CL.
Nomodel derived from the total 1’-hydroxymidazolam
data to predict midazolam CL as a function of a sin-
gle time point 1’-hydroxymidazolam:midazolam
was predictive of midazolam CL. One model pre-
dicted midazolam CL as a function of total
1’-hydroxymidazolam. The equation is as follows:
CL = 445.9 – 65.1 (total 1’-hydroxymidazolam300 min).
The corresponding r2 = 0.29 had a p < 0.0001. This
derived equationwas thenvalidatedwithdata from the
remaining 14 participants. Pearson correlation was
used to compare predicted midazolam CL to observed
midazolam CL (Figure 1). The derived equation could
not be validated (r = 0.29, p = 0.31).
DISCUSSION
Limited sampling has been demonstrated with the use
of midazolam,6,9 and single sampling of omeprazole
and 5-hydroxyomeprazole concentrations 3 hours fol-
lowing drug administration is often used for CYP2C19
phenotyping.10,11 While the limited sampling strategy
for midazolam is more convenient than standard sam-
pling, single sampling would be optimal.
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Table I Demographic Information and Midazolam Clearance by Data Analysis Group for 61 Healthy Adults
Unconjugated 1’-Hydroxymidazolam Group Total 1’-Hydroxymidazolam Group
Derivation Validation Derivation Validation Total
Total subjects 16 17 14 14 61
Male 7 7 14 14
Female 9 10 0 0
Age range (years) 25-51 22-56 25-44 24-43
Age (mean ± SD) 39 ± 8.6 36.7 ± 9.3 33.6 ± 6.1 33.4 ± 5.8
Weight range (kg) 57-102.6 57-124.5 68.2-115.9 75.7-102.7
Weight (mean ± SD) 77.0 ± 16.8 77.8 ± 16.7 88.4 ± 2.2 85 ± 9.1
Height range (cm) 158-184 157-188 165-185 165-193
Height (mean ± SD) 169.4 ± 7.7 170.5 ± 8.9 178.0 ± 7.2 177.5 ± 7.5
Race, n (%)
Caucasian 16(100) 17(100) 7(50) 8(57) 48(79)
African American 0(0) 0(0) 7(50) 6(43) 13(21)
Midazolam clearance
Range (ml/min) 404-718 437-836 194-381 198-391
Mean ± SD 539 ± 87 608 ± 118 282 ± 65 297 ± 55
Median 534 581 266 296























Figure 1. Observed midazolam clearance versus predicted
midazolam clearance based on the 300-minute total
1’-hydroxymidazolam concentration with corresponding Pearson
correlation coefficient (r).
A previous study showed that a single sampling ap-
proach was predictive of midazolam clearance in liver
transplant patients. However, this correlation was
dependent on steroid-induced variability.6 As a re-
sult, the use of this 30-minute ratiowouldmost likely
have minimal utility in predicting midazolam clear-
ance in healthy subjects. The results of our data anal-
yses showed failure of any single sampling time
point of 1’-hydroxymidazolam or the ratio of
1’-hydroxymidazolam:midazolam to predict
midazolam clearance. A possible reason for this failure
is intersubject variability associated with genetic and
environmental factors. Also, midazolam is lipophilic,
and its volume of distribution is increased in obese
subjects.12 Some study participants were obese and
therefore have larger volumes of distribution. In addi-
tion, midazolam is moderately extracted by the liver,
where the hepatic extraction ratio (EH) is 0.3 ≤ EH ≤ 0.7.
As such, the clearance of midazolam is dependent on
CYP3A activity, hepatic blood flow, and the fraction of
unbound midazolam in the plasma. The influence of
all of these factors will add intersubject variability to
resulting midazolam clearance.
Single sampling strategies using 1’-hydroxy-
midazolam:midazolam or 1’- hydroxymidazolam con-
centrations cannot be used to predict midazolamCL in
healthy adults. Minimized sampling (i.e., 5, 30, 360
min) ofmidazolam concentrations remains amore reli-
able method for estimating midazolam AUC.
MidazolamCL can then be calculated and correlated to
hepatic CYP3A activity.
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